Literature DB >> 11431338

Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells.

J Gao1, J T Arnold, J T Isaacs.   

Abstract

Normal adult prostate epithelium of both human and rat origin was transplanted with Matrigel into intact or androgen-ablated (i.e., castrated) nude mice. Within these transplants, an influx of mouse mesenchymal cells was one of the earliest events to occur resulting in the development of a collar of smooth muscle cells and fibroblasts surrounding the transplanted epithelium. A subset of these surrounding stromal cells express androgen receptor (AR). The surrounded transplanted epithelium initially expresses high molecular weight cytokeratins characteristic of prostatic basal cells and AR. In both intact and androgen-ablated hosts, this epithelium subsequently develops a patent lumen producing a rudimentary glandular acini. Only in the nonablated hosts, however, do these rudimentary acini undergo a further proliferative growth phase, as determined by Ki67 immunocytochemical stainings and the development of a low molecular weight cytokeratin positive layer of luminal (i.e., secretory) epithelial cells. Because AR is expressed in both the donor epithelium and host (i.e., mouse) stromal cells, this androgen-stimulated growth response could involve either autocrine pathways initiated within donor normal adult epithelial cells themselves or paracrine pathways initiated within the AR-expressing subset of mouse stromal cells. To resolve this issue, mice carrying the testicular feminized mutation in the X-linked AR gene were cross-bred to AR-wt nude mice to produce AR-null nude male mice. None of the cells in these AR-null nude male mice express functional AR protein. Therefore, these animals can be used to prevent any possibility of host stromal cell paracrine involvement in initiating an androgen-stimulated growth response when normal adult or malignant prostatic epithelial cells are transplanted into these null hosts. In these AR-null nude male mice, the androgen-stimulated growth of normal adult prostatic epithelial cells did not occur (i.e., androgen-induced growth response of normal prostatic epithelial cells requires stromal cell paracrine involvement). In contrast, using four different prostatic cancer models (i.e., human PC-82, human LNCaP, human LAPC-4, and rat R3327G), the androgen-stimulated growth of prostatic cancer cells occurred identically in both AR-null and AR-wt nude male mice (i.e., a direct autocrine mechanism is responsible for androgen-stimulated growth of malignant prostatic epithelial cells). In summary, a fundamental change in the mechanism for androgen-stimulated growth occurs during the transformation from normal to malignant prostatic epithelial cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11431338

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  56 in total

1.  Role of autonomous androgen receptor signaling in prostate cancer initiation is dichotomous and depends on the oncogenic signal.

Authors:  Sanaz Memarzadeh; Houjian Cai; Deanna M Janzen; Li Xin; Rita Lukacs; Mireille Riedinger; Yang Zong; Karel DeGendt; Guido Verhoeven; Jiaoti Huang; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-25       Impact factor: 11.205

2.  Deregulation of a Hox protein regulatory network spanning prostate cancer initiation and progression.

Authors:  James L Chen; Jianrong Li; Kyle J Kiriluk; Alex M Rosen; Gladell P Paner; Tatjana Antic; Yves A Lussier; Donald J Vander Griend
Journal:  Clin Cancer Res       Date:  2012-06-21       Impact factor: 12.531

3.  Androgen-induced PSA expression requires not only activation of AR but also endogenous IGF-I or IGF-I/PI3K/Akt signaling in human prostate cancer epithelial cells.

Authors:  Xunxian Liu; Renee Y Choi; Shayma M Jawad; Julia T Arnold
Journal:  Prostate       Date:  2010-10-28       Impact factor: 4.104

4.  The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells.

Authors:  Donald J Vander Griend; Wouter L Karthaus; Susan Dalrymple; Alan Meeker; Angelo M DeMarzo; John T Isaacs
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

5.  Dual-label centromere and telomere FISH identifies human, rat, and mouse cell contribution to Multispecies recombinant urogenital sinus xenografts.

Authors:  Donald J Vander Griend; Yuko Konishi; Angelo M De Marzo; John T Isaacs; Alan K Meeker
Journal:  Prostate       Date:  2009-10-01       Impact factor: 4.104

Review 6.  Differing levels of testosterone and the prostate: a physiological interplay.

Authors:  S Larry Goldenberg; Anthony Koupparis; Michael E Robinson
Journal:  Nat Rev Urol       Date:  2011-05-31       Impact factor: 14.432

7.  Oestrogen supplementation following castration promotes stromal remodelling and histopathological alterations in the Mongolian gerbil ventral prostate.

Authors:  Wellerson Rodrigo Scarano; Daniel Emídio de Sousa; Silvana Gisele Pegorin Campos; Lara Silvia Corradi; Patricia Simone Leite Vilamaior; Sebastião Roberto Taboga
Journal:  Int J Exp Pathol       Date:  2007-11-10       Impact factor: 1.925

8.  Rational design of novel antiandrogens for neutralizing androgen receptor function in hormone refractory prostate cancer.

Authors:  Pratap Singh; Gurulingappa Hallur; Ravi K Anchoori; Oladapo Bakare; Yukio Kageyama; Saeed R Khan; John T Isaacs
Journal:  Prostate       Date:  2008-10-01       Impact factor: 4.104

9.  Neuroendocrine differentiation in prostate cancer.

Authors:  Yin Sun; Junyang Niu; Jiaoti Huang
Journal:  Am J Transl Res       Date:  2009-02-05       Impact factor: 4.060

10.  Suppression of DHT-induced paracrine stimulation of endothelial cell growth by estrogens via prostate cancer cells.

Authors:  Juan Wen; Yuan Zhao; Jinghe Li; Chunyan Weng; Jingjing Cai; Kan Yang; Hong Yuan; Julianne Imperato-McGinley; Yuan-Shan Zhu
Journal:  Prostate       Date:  2013-02-19       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.